We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
+$36.5M
Cap. Flow %
3.32%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.88%
2 Healthcare 12.71%
3 Financials 0.19%
4 Technology 0.09%
5 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
176
PUT
Insmed
INSM
$26.2B
– –
-1,851
Closed -$5.78M
KPRX icon
177
Kiora Pharmaceuticals
KPRX
$11.5M
– –
-9
Closed -$54K
KRYS icon
178
Krystal Biotech
KRYS
$9.97B
– –
-53,558
Closed -$534K
KZIA
179
Kazia Therapeutics
KZIA
$161M
$0 ﹤0.01%
+7,333
New +$1.08M
NTLA icon
180
Intellia Therapeutics
NTLA
$1.59B
– –
-11,281
Closed -$280K
OEF icon
181
PUT
iShares S&P 100 ETF
OEF
$20.1B
– –
-5,980
Closed -$88.6M
PTCT icon
182
CALL
PTC Therapeutics
PTCT
$5.48B
– –
-1,277
Closed -$2.56M
SCNI
183
Scinai Immunotherapeutics
SCNI
$1.04M
– –
-19
Closed -$139K
SPY icon
184
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$799B
– –
-5,000
Closed -$126M
UTHR icon
185
CALL
United Therapeutics
UTHR
$21.5B
– –
-542
Closed -$6.35M
WVE icon
186
Wave Life Sciences
WVE
$879M
– –
-75,000
Closed -$1.63M
NTRP icon
187
NextTrip
NTRP
$27.2M
– –
-350
Closed -$132K
HURA
188
TuHURA Biosciences
HURA
$129M
– –
-121
Closed -$1.78M
IRD
189
Opus Genetics
IRD
$484M
– –
-3,540
Closed -$411K
LUMO
190
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-111
Closed -$1.02M
LUMO
191
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-14
Closed -$124K
NBSE
192
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-380
Closed -$110K
DMK
193
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-1,434
Closed -$524K
DMK
194
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-8
Closed -$300K
ARAV
195
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-105
Closed -$155K
SGEN
196
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-542
Closed -$2.95M
SGEN
197
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-42,646
Closed -$2.32M
SGEN
198
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-1,734
Closed -$9.44M
ACGN
199
CALL
DELISTED
Aceragen Inc
ACGN
– –
0
– -$93K
OTIC
200
CALL
DELISTED
Otonomy, Inc.
OTIC
– –
-275
Closed -$89K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management deployed $36.5M of net new capital in Q4 2017, opening 63 new positions and adding to 36 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 92% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $3.2M trimmed.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.